SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2009 / Cilt: 9 - Sayı: 2

İskemik kalp hastalığı olan hastalarda serum interlökin (IL)-13, IL–17 ve IL–18 düzeyleri

Serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease

Ali ESMAEELI-NADİMI
Hossain NOUGH
Maryam NEMATI
Mohammad Taghi REZAYATİ
Abdollah JAFARZADEH
Pages
75–83
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The frequency of subjects with detectable levels of IL-13 in control group was significantly higher as compared to AMI group and total group of patients with IHD (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: It has been reported that the cytokines play an important role in the pathogenesis of cardiovascular diseases.
📊
Key Findings & Data:The aim of this study was to evaluate the serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease (IHD) and also to clarify their association with traditional risk factors of disease.
💡
Conclusion & Impact:The frequency of subjects with detectable levels of IL-13 in control group was significantly higher as compared to AMI group and total group of patients with IHD (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: It has been reported that the cytokines play an important role in the pathogenesis of cardiovascular diseases. The aim of this study was to evaluate the serum levels of interleukin (IL)-13, IL-17 and IL-18 in patients with ischemic heart disease (IHD) and also to clarify their association with traditional risk factors of disease. Methods: A total of 60 patients with IHD as having acute myocardial infarction (AMI; n=30) or unstable angina (UA; n=30) and 30 sex- and age- matched healthy subjects as a control group were enrolled to this cross-sectional, case-controlled study. Serum samples were collected from all participants (for AMI patients at 3-5 days after events and for UA at admission time) and tested for the IL-13, IL-17 and IL-18 by use of ELISA method. Statistical analysis was performed using ANOVA, Student t, Kruskal-Wallis, Mann-Whitney U and Chi-square tests as appropriate. Results: The frequencies of subjects with detectable levels of IL-13 were 6.7%, 20% and 33.3% in AMI, UA and control groups, respectively. The frequency of subjects with detectable levels of IL-13 in control group was significantly higher as compared to AMI group and total group of patients with IHD (p

Özet

Amaç: Kalp ve damar hastalıklarının patogenezinde sitokinlerin önemli bir rol oynadığı rapor edilmektedir. Bu çalışmanın amacı iskemik kalp hastalığında (İKH) IL-13, IL-17 ve IL-18’in serum düzeylerini değerlendirmek ve bunların geleneksel risk faktörleri ile birlikteliğini açığa kavuşturmaktı. Yöntemler: Akut miyokard infarktüsü (AMİ) (n=30) veya kararsız anginası (KA) (n=30) olan toplam 60 IKH’li hasta ile yaş ve cinsiyeti denk olan 30 sağlıklı kişi kontrol grubu olarak bu enine-kesitli, vaka-kontrollü çalışmaya dâhil edildi. Tüm katılanlardan (AMİ hastaları için olaydan 3-5 gün sonra ve KA için kabullerinde) serum örnekleri toplanarak ELISA yöntemi ile IL-13, IL-17 ve IL-18 ölçümü yapıldı. Uygunluklarına göre, istatistiksel analizinde ANOVA, Student-t, Kruskal- Wallis, Mann-Whitney U ve c2 testleri yapıldı. Bulgular: Interlökin-13 saptanabilen kişi sıklığı AMİ, KA ve kontrol gruplarında, sırası ile %6.7, %20 ve %33.3 idi. Kontrol grubunda saptanabilen IL-13’lü kişilerin sıklığı AMİ ve İKH olan hastalar ile karşılaştırıldığında istatistiksel olarak daha fazla idi (sırası ile p

🔖

Cite This Article

ESMAEELI-NADİMI, A., NOUGH, H., NEMATI, M., REZAYATİ, M. T., JAFARZADEH, A. (2022). İskemik kalp hastalığı olan hastalarda serum interlökin (IL)-13, IL–17 ve IL–18 düzeyleri. Anadolu Kardiyoloji Dergisi, Cilt: 9 - Sayı: 2, 75–83. https://ajindex.com/articles/436898

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Tiong AY, Brieger D. Inflammation and coronary artery disease. Am Heart J 2005; 150: 11-8
  2. Mahmoudi M, Curzen N, Gallagher PJ. Atherogenesis: the role of inflammation and infection. Histopathol 2007; 50: 535-46
  3. Baidya SG, Zeng QT. Helper T cells and atherosclerosis: the cytokine web. Postgrad Med J 2005; 81: 746-52
  4. Skapenko A, Schulze-Koops H. Analysis of Th1/Th2 T-cell subsets. Methods Mol Med 2007; 136: 87-96
  5. Santana M, Rosenstein Y. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J Cell Physiol 2003; 195: 392-401
  6. Cheng X, Liao YH, Ge H, Li B, Zhang J, Yuan J, et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol 2005; 25: 246-53
  7. Pasqui AL, Di Renzo M, Auteri A, Puccetti L. Cytokines in acute coronary syndromes. Int J Cardiol 2005; 105: 355-6
  8. Steppich BA, Moog P, Matissek C, Wisniowski N, Kühle J, Joghetaei N, et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2007; 190: 443-51
  9. Schmidt-Weber CB, Akdis M, Akdis CA. TH17 cells in the big picture of immunology. J Allergy Clin Immunol 2007; 120: 247-54
  10. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19: 281-6
  11. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006; 17: 699-706
  12. Ridker PM, Genest G, Libby P. Risk factors for atherosclerotic disease. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease: a Textbook of Cardiovascular Medicine. 6th ed. Philadelphia: Saunders; 2001. p. 1028-31
  13. Chen MC, Chen CJ, Yang CH, Wu CJ, Fang CY, Hsieh YK et al. Interleukin-18: a strong predictor of the extent of coronary artery disease in patients with unstable angina. Heart Vessels 2007; 22: 371-5
  14. Rosso R, Roth A, Herz I, Miller H, Keren G, George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol 2005; 98: 45-8
  15. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 195: 245-57
  16. Kawasaki D, Tsujino T, Morimoto S, Masai M, Masutani M, Ohyanagi M, et al. Plasma interleukin